5-Amino-1MQ

5-Amino-1MQ is a small-molecule research compound (often grouped with metabolic “peptide” stacks) studied primarily as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide metabolism and cellular methylation balance. NNMT overexpression has been associated with metabolic dysfunction in adipose tissue and liver, and NNMT inhibition is being investigated for potential effects on energy expenditure, insulin sensitivity, and body-composition outcomes in preclinical models.

— 10 mg Vial —

Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration.
Typical dose: 1–5 mg once daily (subcutaneous).
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, use within 2–4 weeks.

Schedule: Daily subcutaneous injections; each 10 mg vial provides 2–10 days of material.

Frequency: Inject once daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) split dosing may provide more sustained NNMT inhibition.

— 50 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → 16.7 mg/mL concentration.
Typical dose: 1–5 mg once or twice daily (subcutaneous).
Easy measuring: At 16.7 mg/mL, 1 unit = 0.01 mL = 0.167 mg (167 mcg) on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, use within 2–4 weeks.

Schedule: Daily subcutaneous injections; each 50 mg vial provides 10–20 days of material.

Frequency: Inject once daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) split dosing may provide more sustained NNMT inhibition.

• NNMT inhibition in adipose tissue and liver (target pathway implicated in obesity and insulin resistance in preclinical research).
• May increase energy expenditure and improve body-weight outcomes in diet-induced obesity models (preclinical).
• May improve glucose tolerance/insulin sensitivity markers in animal studies (preclinical).
• May influence NAD+ precursor handling by reducing NNMT-driven nicotinamide “sink” (mechanistic hypothesis).
• Potential effects on hepatic steatosis markers in metabolic disease models (preclinical).
• Often researched as part of “metabolic” stacks to target multiple nodes of energy balance (speculative).

NNMT catalyzes methylation of nicotinamide (NAM) to 1-methylnicotinamide using S-adenosylmethionine (SAM) as the methyl donor. By inhibiting NNMT, 5-Amino-1MQ is hypothesized to reduce NAM diversion into 1-methylnicotinamide, potentially preserving NAM for NAD+ salvage pathways and reducing methyl-donor drain (SAM consumption). In adipose and liver models, NNMT inhibition has been linked to higher energy expenditure and improved metabolic signaling, though translation to humans remains uncertain.

Potential adverse effects reported in literature and/or anecdotally include:

• GI upset (nausea, loose stools) reported anecdotally.
• Headache or dizziness.
• Sleep disturbance or stimulation in sensitive individuals.
• Changes in appetite.
• Unknown long-term safety; limited human clinical data.

• Start at the low end and titrate slowly.
• Take with food if GI upset occurs.
• Avoid late-day dosing if sleep disruption occurs.
• Discontinue if persistent headaches, dizziness, or adverse symptoms occur.
• Avoid stacking multiple new agents at once.

• Pregnancy or breastfeeding (no safety data).
• Age <18 (no safety data).
• Known liver or kidney disease (unknown metabolism/clearance).
• Active cancer without clinician oversight (NNMT implicated in tumor biology; risk unknown).
• Use caution with drugs/supplements affecting methylation/NAD pathways; interactions unclear.

PubMed-linked citations for verification. Many studies are preclinical (animal/in-vitro).

1. NNMT regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med. 2018. PMID: 29400715 (doi: 10.1038/s41591-018-0006-4)
2. Nicotinamide N-methyltransferase: a promising metabolic target in obesity and insulin resistance. Endocr Rev. 2021. PubMed
3. NNMT at the intersection of NAD metabolism and methyl-donor balance (review). Cell Metab. PubMed